GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Brain and Nervous System
What is the purpose of this trial?
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
- Trial withGlobal Coalition for Adaptive Research
- Start Date07/15/2020
- End Date12/30/2022
- Last Updated08/16/2020
- Study HIC#2000026339